

Berlex Laboratories Incorporated

[View the current Berlex Laboratories Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/1337-Berlex+Laboratories+Incorporated.html)

(<http://www.bioportfolio.com/bioporcorporate/1337-Berlex+Laboratories+Incorporated.html>)

Contact Details:

2600 Hilltop Drive

Richmond

CA

94806

United States of America

Tel: 510 262 5000

Fax: 510 262 7095

Email:

Berlex Laboratories, Inc., located in Wayne and Montville, NJ and Richmond, CA, is committed to bringing to the market beneficial preventive, diagnostic and therapeutic medicines in the strategic fields of Dermatology, Diagnostic Imaging, Female Healthcare, Therapeutics and Oncology. Driving our activities is a three-pronged emphasis on recognizing and addressing marketplace needs, improving the quality of life for patients and building strong relationships with the healthcare professionals who select and administer our pharmaceutical products.

Recent Publications by Berlex Laboratories Incorporated:



- [A summary of safety of gadofosveset \(MS-325\) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.](#)
*OBJECTIVE: We sought to summarize the Phase II and Phase III clinical...*4th April, 2008
Medical Development Diagnostic Imaging and Radiopharmaceuticals, Berlex- Invest Radiol. 2006 Nov;41(11):822-30. ([DOI Direct Link](#))
- [High-performance liquid chromatography method for rapid assessment of viral particle number in crude adenoviral lysates of mixed serotype.](#)
*Accurate adenovirus (Ad) quantification requires labor- and time-intensive...*19th August, 2007
Berlex Laboratories, Gene Therapy Department, Richmond, CA 94806, USA.- Gene Ther. 2007 Jan;14(2):180-4. Epub 2006 Oct 5. ([DOI Direct Link](#))
- [Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors.](#)
*BACKGROUND: The Hedgehog (Hh) signaling pathway regulates a variety of...*13th November, 2004
Department of Gene Therapy, Berlex Laboratories, Inc, Richmond, CA 94806,- BMC Cancer. 2004 Aug 4;4:43. ([DOI Direct Link](#))

- [Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.](#)
*The goal of this investigation was to evaluate the performance of a novel...*9th August, 2003
Berlex Laboratories, Inc, 340 Changebridge Road, Montville, NJ 07045, USA.- Biopharm Drug Dispos. 2003 Jan;24(1):1-16. ([DOI Direct Link](#))
- [Electrocardiographic effects of diagnostic imaging agents.](#)
*The goal of this investigation was to evaluate the performance of a novel...*26th February, 2003
Berlex Laboratories, Montville, NJ 07470-1000, USA.- Acad Radiol. 2002 Aug;9 Suppl 2:S444-6.
- [Comparison of bracketing and matrixing designs for a two-year stability study.](#)
*In the U.S. Food and Drug Administration (FDA) guidelines for stability...*15th July, 2000
Berlex Laboratories, Inc., Montville, New Jersey 07045-1000, USA.- J Biopharm Stat. 2000 May;10(2):217-28.

Berlex Laboratories Incorporated Patents:



- 5994375- [Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants](#)
- 6166088- [Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants](#)
- 6177473- [Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants](#)
- 6221886- [Thio acid derived monocyclic N-heterocyclics as anticoagulants](#)
- 6232325- [Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants](#)
- 6242454- [Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants](#)
- 6248304- [Scintigraphic imaging agents](#)
- 6262088- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6265404- [Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants](#)
- 6274091- [Apparatus and process for multiple chemical reactions](#)
- 6306884- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6166014- [Thio acid derived monocyclic N-heterocyclics as anticoagulants](#)
- 6162807- [Thio acid derived monocyclic N-heterocyclics as anticoagulants](#)
- 6150382- [Thio acid derived monocyclic n-heterocyclics as anticoagulants](#)
- 6004981- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6004985- [Thio acid derived monocyclic N-heterocyclics as anticoagulants](#)
- 6008234- [Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants](#)
- 6009875- [Use of sympathetic antagonists for treatment of chronic muscle pain](#)
- 6034084- [Thio acid derived monocyclic N-heterocyclics as anticoagulants](#)
- 6034103- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6071912- [Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants](#)
- 6123939- [Anti-neoplastic drugs in cancer therapy](#)

- 6127376- [Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants](#)
- 6140351- [Ortho-anthranilamide derivatives as anti-coagulants](#)
- 6350746- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6350761- [Benzenamine derivatives as anti-coagulants](#)
- 6686364- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6686367- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6692763- [Methods for treating postmenopausal women using ultra-low doses of estrogen](#)
- 6747031- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6841673- [N-heterocyclic derivatives as nos inhibitors](#)
- 6841674- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6846829- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6849739- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6864263- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6884418- [Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy](#)
- 6670473- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6559147- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6552030- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6358491- [Somatostatin analogs](#)
- 6372751- [Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants](#)
- 6380221- [Ortho-anthranilamide derivatives as anti-coagulants](#)
- 6432947- [N-heterocyclic derivatives as NOS inhibitors](#)
- 6465459- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6479485- [Benzamidine derivatives and their use as anti-coagulants](#)
- 6492376- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6495574- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6495684- [Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants](#)
- 6498185- [Ortho-anthranilamide derivatives as anti-coagulants](#)
- 6887865- [N-heterocyclic derivatives as NOS inhibitors](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

